Persistence of Botulinum neurotoxin inactivation of nerve function

Current Topics in Microbiology and Immunology

Volumn 364, Issue , 2013, Pages 179-196

  Shoemaker, Charles B ^a   Oyler, George A ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Botulinum neurotoxin light chain; E3 ligase; Persistence; Polyubiquitination; TRAF2

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN E; PROTEASOME; PROTEINASE; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UBIQUITIN; HYBRID PROTEIN; NEUROTOXIN; PEPTIDE HYDROLASE;

ARTICLE; BOTULISM; CELL MEMBRANE TRANSPORT; COMPLEX FORMATION; CYTOSOL; ENZYME LOCALIZATION; ENZYME METABOLISM; EXOCYTOSIS; HEAVY CHAIN; HUMAN; LIGHT CHAIN; NERVE FUNCTION; NEUROSECRETION; NEUROTOXICITY; NONHUMAN; PARALYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN TARGETING; SYNAPTIC INHIBITION; TOXICOKINETICS; TOXIN ANALYSIS; UBIQUITINATION; ANIMAL; CLOSTRIDIUM BOTULINUM; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; HALF LIFE TIME; METABOLISM; MICROBIOLOGY; MOTONEURON; PATHOGENICITY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; SEQUENCE ANALYSIS; TOXICITY TESTING;

ANIMALS; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; ENZYME ACTIVATION; EXOCYTOSIS; HALF-LIFE; HUMANS; MOTOR NEURONS; NEUROTOXINS; PARALYSIS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS; SEQUENCE ANALYSIS, PROTEIN; SNARE PROTEINS; TNF RECEPTOR-ASSOCIATED FACTOR 2; TOXICITY TESTS; UBIQUITINATION;

EID: 84875814383     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-33570-9-9     Document Type: Article

References (59)

1. Adler M, Macdonald DA, Sellin LC, Parker GW (1996) Effect of 3, 4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon: Official J Int Soc Toxinology 34:237-249
2. Adler M, Keller JE, Sheridan RE, Deshpande SS (2001) Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon: Official J Int Soc Toxinology 39:233-243
3. Ahnet-Hilger G, Münster-Wandowski A, Höltje M (2012) Synaptic vesicle proteins: targets and routes for botulinum neurotoxins. doi:10.1007/978-3-642-33570-9-8
4. Aiken C, Konner J, Landau NR, Lenburg ME, Trono D (1994) Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 76:853-864
5. Angaut-Petit D, Molgo J, Comella JX, Faille L, Tabti N (1990) Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 37:799-808
6. Bade S, Rummel A, Reisinger C, Karnath T, Ahnert-Hilger G et al (2004) Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J Neurochem 91:1461-1472
7. Bajohrs M, Rickman C, Binz T, Davletov B (2004) A molecular basis underlying differences in the toxicity of botulinum serotypes A and E. EMBO Rep 5:1090-1095
8. Bartels F, Bergel H, Bigalke H, Frevert J, Halpern J et al (1994) Specific antibodies against the Zn (2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin. J Biol Chem 269:8122-8127
9. Binz (2012) Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. doi:10.1007/978-3-642-33570-9-7
10. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA et al (1999) Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53:1431-1438
11. Brown MC, Holland RL, Hopkins WG (1981) Motor nerve sprouting. Annu Rev Neurosci 4:17-42
12. Chen ZJ (2005) Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7:758-765
13. Chen S, Barbieri JT (2011) Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25. J Biol Chem 286:15067-15072
14. Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79-87
15. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO (1999) Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 96:3200-3205
16. Dolly JO, Lisk G, Foran PG, Meunier F, Mohammed N, O'Sullivan G, de Paiva A (2002) Insights into the extended duration of neuroparalysis by Botulinum Neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In: Brin MF, Hallett M, Jankovic J (ed) Scientific and therapeutic aspects of Botulinum Toxin. Lippincott Williams and Wilkins, Philadelphia, pp 91-102
17. Eiklid K, Olsnes S, Pihl A (1980) Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 126:321-326
18. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D (1997) Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 224:91-94
19. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135-138
20. Erdal E, Bartels F, Binscheck T, Erdmann G, Frevert J et al (1995) Processing of tetanus and botulinum A neurotoxins in isolated chromaffin cells. Naunyn-Schmiedeberg's Arch Pharmacol 351:67-78
21. Fernandez-Salas E, Steward LE, Ho H, Garay PE, Sun SW et al (2004a) Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A 101:3208-3213
22. Fernandez-Salas E, Ho H, Garay P, Steward LE, Aoki KR (2004b) Is the light chain subcellular localization an important factor in botulinum toxin duration of action? Mov Disord 19(Suppl 8):S23-S34
23. Ferrer-Montiel AV, Gutierrez LM, Apland JP, Canaves JM, Gil A et al (1998) The 26-mer peptide released from SNAP-25 cleavage by botulinum neurotoxin E inhibits vesicle docking. FEBS Lett 435:84-88
24. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW et al (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278:1363-1371
25. Gutierrez LM, Canaves JM, Ferrer-Montiel AV, Reig JA, Montal M et al (1995) A peptide that mimics the carboxy-terminal domain of SNAP-25 blocks Ca (2+)-dependent exocytosis in chromaffin cells. FEBS Lett 372:39-43
26. Gutierrez LM, Viniegra S, Rueda J, Ferrer-Montiel AV, Canaves JM et al (1997) A peptide that mimics the C-terminal sequence of SNAP-25 inhibits secretory vesicle docking in chromaffin cells. J Biol Chem 272:2634-2639
27. Hanig JP, Lamanna C (1979) Toxicity of botulinum toxin: a stoichiometric model for the locus of its extraordinary potency and persistence at the neuromuscular junction. J Theor Biol 77:107-113
28. Hayashi T, McMahon H, Yamasaki S, Binz T, Hata Y et al (1994) Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J 13:5051-5061
29. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479
30. Hill KK, Smith TJ (2012) Genetic diversity within Clostridium botulinum serotypes, botulinum Nneurotoxin gene clusters and toxin subtypes. doi:10.1007/978-3-642-33570-9-1
31. Huang X, Wheeler MB, Kang YH, Sheu L, Lukacs GL et al (1998) Truncated SNAP-25(1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells. Mol Endocrinol 12:1060-1070
32. Kauffman JA, Way JF Jr, Siegel LS, Sellin LC (1985) Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction. Toxicol Appl Pharmacol 79:211-217
33. Keller JE (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139:629-637
34. Keller JE, Neale EA, Oyler G, Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137-142
35. Krautz-Peterson G, Zhang Y, Chen K, Oyler GA, Feng H et al (2012) Retargeting Clostridium difficile Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism. J Toxicol 2012:760142
36. Kuo CL, Oyler GA, Shoemaker CB (2011) Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination. PLos ONE (in press)
37. Land J, Zhang H, Vaidyanathan VV, Sadoul K, Niemann H et al (1997) Transient expression of botulinum neurotoxin C1 light chain differentially inhibits calcium and glucose induced insulin secretion in clonal beta-cells. FEBS Lett 419:13-17
38. Mehta PP, Battenberg E, Wilson MC (1996) SNAP-25 and synaptotagmin involvement in the final Ca (2+)-dependent triggering of neurotransmitter exocytosis. Proc Natl Acad Sci U S A 93:10471-10476
39. Meunier FA, Schiavo G, Molgo J (2002) Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 96:105-113
40. Meunier FA, Lisk G, Sesardic D, Dolly JO (2003) Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Molecular and cellular neurosciences 22:454-466
41. Montal M (2010) Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79:591-617
42. Morbiato L, Carli L, Johnson EA, Montecucco C, Molgo J et al (2007) Neuromuscular paralysis and recovery in mice injected with botulinum neurotoxins A and C. Eur J Neurosci 25:2697-2704
43. O'Sullivan GA, Mohammed N, Foran PG, Lawrence GW, Oliver Dolly J (1999) Rescue of exocytosis in botulinum toxin A-poisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues. J Biol Chem 274:36897-36904
44. Otto H, Hanson PI, Chapman ER, Blasi J, Jahn R (1995) Poisoning by botulinum neurotoxin A does not inhibit formation or disassembly of the synaptosomal fusion complex. Biochem Biophys Res Commun 212:945-952
45. Raciborska DA, Charlton MP (1999) Retention of cleaved synaptosome-associated protein of 25 kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning. Can J Physiol Pharmacol 77:679-688
46. Sellin LC, Kauffman JA, Dasgupta BR (1983) Comparison of the effects of botulinum neurotoxin types A and E at the rat neuromuscular junction. Med biol 61:120-125
47. Shi X, Curran JE, Liao Z, Gordon RK (2009) The biological activity of ubiquitinated BoNT/B light chain in vitro and in human SHSY-5Y neuronal cells. J Cell Biochem 108:660-667
48. Sloop RR, Cole BA, Escutin RO (1997) Human response to botulinum toxin injection: type B compared with type A. Neurology 49:189-194
49. Tremblay JM, Kuo CL, Abeijon C, Sepulveda J, Oyler G et al (2010) Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon: Official J Int Soc Toxinology 56:990-998
50. Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB et al (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci U S A 107:16554-16559
51. Varshavsky A (1996) The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci U S A 93:12142-12149
52. Wang J, Meng J, Lawrence GW, Zurawski TH, Sasse A et al (2008) Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem 283:16993-17002
53. Wang J, Zurawski TH, Meng J, Lawrence G, Olango WM et al (2011) A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 286:6375-6385
54. Wang J, Zurawski TH, Bodeker MO, Meng J, Boddul S et al (2012) Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Biochem J 444:59-67
55. Webb RP, Smith TJ, Wright P, Brown J, Smith LA (2009) Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27:4490-4497
56. Westbrook TF, Hu G, Ang XL, Mulligan P, Pavlova NN et al (2008) SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 452:370-374
57. Whittaker RL, Gilbertson RB, Garrett AS Jr (1964) Botulism, type E; report of eight simultaneous cases. Ann Intern Med 61:448-454
58. Wong E, Cuervo AM (2010) Integration of clearance mechanisms: the proteasome and autophagy. Cold Spring Harbor perspectives in biology 2:a006734
59. Yamaizumi M, Mekada E, Uchida T, Okada Y (1978) One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 15:245-250